MX2009005793A - Interferon alpha-induced pharmacodynamic markers. - Google Patents

Interferon alpha-induced pharmacodynamic markers.

Info

Publication number
MX2009005793A
MX2009005793A MX2009005793A MX2009005793A MX2009005793A MX 2009005793 A MX2009005793 A MX 2009005793A MX 2009005793 A MX2009005793 A MX 2009005793A MX 2009005793 A MX2009005793 A MX 2009005793A MX 2009005793 A MX2009005793 A MX 2009005793A
Authority
MX
Mexico
Prior art keywords
ifnî
induced
patients
ifn
methods
Prior art date
Application number
MX2009005793A
Other languages
Spanish (es)
Inventor
Bahija Jallal
Peter Kiener
Anthony Coyle
Yihong Yao
Ricardo Cibotti
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Priority claimed from PCT/US2007/024947 external-priority patent/WO2008070137A2/en
Publication of MX2009005793A publication Critical patent/MX2009005793A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention encompasses type-1 IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα- mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.
MX2009005793A 2006-12-06 2007-12-06 Interferon alpha-induced pharmacodynamic markers. MX2009005793A (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US87300806P 2006-12-06 2006-12-06
US90776207P 2007-04-16 2007-04-16
US92422007P 2007-05-03 2007-05-03
US92421907P 2007-05-03 2007-05-03
US92458407P 2007-05-21 2007-05-21
US96018707P 2007-09-19 2007-09-19
US99617407P 2007-11-05 2007-11-05
US99617607P 2007-11-05 2007-11-05
US99621907P 2007-11-06 2007-11-06
US99682007P 2007-12-06 2007-12-06
PCT/US2007/024947 WO2008070137A2 (en) 2006-12-06 2007-12-06 Interferon alpha-induced pharmacodynamic markers
PCT/US2007/024941 WO2008070135A2 (en) 2006-12-06 2007-12-06 Methods of treating systemic lupus erythematosus
US90776709P 2009-04-16 2009-04-16

Publications (1)

Publication Number Publication Date
MX2009005793A true MX2009005793A (en) 2009-07-10

Family

ID=41559078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005793A MX2009005793A (en) 2006-12-06 2007-12-06 Interferon alpha-induced pharmacodynamic markers.

Country Status (1)

Country Link
MX (1) MX2009005793A (en)

Similar Documents

Publication Publication Date Title
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
CY1118566T1 (en) DIAGNOSIS USING INTERFERENCE TYPE 1
WO2008079326A3 (en) Methods for using and identifying modulators of delta-like 4
BRPI0512500A (en) treatment or conditions involving demyelination
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
CY1111714T1 (en) Binding Protein Growth Factor (HGF) Binding Proteins.
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
WO2009100342A3 (en) Disease markers and uses thereof
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
UY28933A1 (en) COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
RS20050035A (en) Therapies for renal failure using interferon-betha
TW200531679A (en) Methods of modulating cytokine activity; related reagents
ATE553778T1 (en) ANTIBODIES SPECIFIC TO HUMAN HEPCIDIN
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
ATE424560T1 (en) MARKER FOR NEUROMYELITIS OPTICA
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
PL1889920T3 (en) In vitro cancer therapy compound identification method
RS51069B (en) Use of oxycodone for treating visceral pain
EP2175879A4 (en) Treatment of prion protein related diseases
UA96926C2 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
ATE555814T1 (en) RADIOACTIVE AGENTS FOR IN VIVO PET IMAGING OF CCR5

Legal Events

Date Code Title Description
FG Grant or registration